New Study: Nmn Supplementation Activates Longevity Proteins To Reduce Stem Cell Senescence And Restore Mitochondrial Function
The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial
Medical
Disease
What Happens When Eye Cancer Usually Spreads? What Exactly Are The Symptoms Of Eye Cancer?
Eye cancer is a very dangerous disease, and as the disease develops, it will affect the patient's body more and more, so it is important for eye cancer patients to receive timely treatment.
Apparatus
New Drug Expected For Patients With Low HER2 Expression, FDA Grants Priority Review Status To Enhertu
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
Apparatus
Two-Drug Combination For Refractory Thyroid Cancer, 100% Effective!
Data from a study presented at the annual meeting of the European Society of Medical Oncology in 2022 showed that lenvatinib in combination with Pembrolizumab could give 100% efficacy in this group of patients.
Disease
Can i Still Have Surgery For Pancreatic Cancer With Portal Vein Invasion? What Are The Symptoms Of Pancreatic Cancer And How Can It Be Detected?
Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.
Apparatus
Two-Drug Combination For Specific Mutation Colorectal Cancer With 100% Efficiency!
A study at Massachusetts General Hospital in the US demonstrated that Adagrasib alone and in combination with cetuximab delivered good results in patients with advanced colorectal cancer with KRAS G12C mutations, with 46% of subjects experiencing substantial tumour shrinkage and an efficacy rate of 100%.
Medical
Frequent CT After Lung Cancer Surgery For Fear Of Recurrence?
For many patients after early lung cancer surgery, it is common for them to worry about recurrence. For this reason, many patients tend to undergo CT examinations more closely to ensure that they have not had a recurrence. However, a recent new study conducted by researchers from Washington University School of Medicine in St. Louis found that even with more frequent CT reviews, post-operative outcomes for lung cancer did not improve...
Apparatus
FDA Grants Orphan Drug Status To Two New Therapies In a Row, And These Two Groups Of Patients Are Expected To Benefit!
Recently, the US FDA has granted orphan drug status to two new therapeutics in a row. One is a small molecule inhibitor, PCLX-001, for the treatment of acute myeloid leukaemia; the other is a T-cell therapy, ET140203, for the treatment of hepatoblastoma. Both therapies are currently in relevant trials.
Apparatus
Ovarian Cancer Heavyweight Cutting-Edge ADC Drug Elahere Proven Safe And Effective
On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.
Apparatus
New Drug For IDH1 Mutation/Relapsed/Refractory Acute Myeloid Leukaemia With Good Complete Remission Rates And Manageable Toxicity
The results of a new study recently showed that Olutasidenib monotherapy in patients with relapsed/refractory acute myeloid leukaemia carrying the IDH1 mutation elicited high rates of complete remission with manageable toxicity.